MRUS | Merus N.V. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	48.12 - 50.39
52 Week Range	19.81 - 61.61
Beta	1.37
Implied Volatility	54.11%
IV Rank	15.87%
Day's Volume	772,864
Average Volume	660,154
Shares Outstanding	68,210,500
Market Cap	3,410,525,000
Sector	Healthcare
Industry	Biotechnology
IPO Date	2016-05-19

Valuation
Profitability
Growth
Health
P/E Ratio	-17.30
Forward P/E Ratio	N/A
EPS	-2.89
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	172
Country	Netherlands
Website	MRUS

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

MRUS's peers: ALVR, BCYC, CLGN, CRNX, ENLV, ENTA, FGEN, IMTX, INBX, KRON, KURA, LRMR, LYEL, MDWD, MRSN, ANEB, ADAG, ACRV, ANAB, MLYS, PTGX, REPL, CERE, PCVX, SNDX, STRO, QURE, RCKT, VCEL, VCYT, VRDN, XENE, XNCR, YMAB, PROK, NAMS

*Chart delayed

Analyzing fundamentals for MRUS we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see MRUS Fundamentals page.

Watching at MRUS technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, but short-term trend is bearish. More technicals details can be found on MRUS Technicals page.